BioSpace News Archive

Doctors and scientists with City of Hope, one of the largest cancer research and treatment organizations in the United States, presented data on potential new treatment options for hematological cancers and a way to predict disease outcomes in patients with diffuse large B cell lymphoma, as well as novel therapies targeting complications like post-transplant infections at this year’s ASH conference in New Orleans, Dec. 10 to 13.

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV).

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; “NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, to host fiscal Fourth Quarter Corporate Update for the period ended September 30, 2022.

Champions Oncology, Inc., a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, announced its financial results for its second quarter of fiscal 2023, ended October 31, 2022.

Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced that it has commenced an underwritten public offering of 3,000,000 of its ordinary shares.

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces that the company expects to receive CLIA certification in during first quarter 2023.

Novanta Inc. (Nasdaq: NOVT) (the “Company”) announced today that Robert Buckley, Chief Financial Officer, and Chuck Ravetto, Group President, are scheduled to present at the CJS Securities 23rd Annual New Ideas for the New Year Investor Conference on Wednesday, January 11, 2023, which is being held virtually.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction (HFrEF).

SK Biopharmaceuticals, an innovative global pharmaceutical company, held a media briefing to introduce its roadmap and vision for its digital healthcare business in Seoul, Korea, ahead of CES 2023, January 5-8 in Las Vegas.

BIOTRONIK, a global leader in the treatment of cardiac and vascular disease is pleased to announce the first patient enrollment in BIO-CONDUCT, an FDA approved investigational device exemption (IDE) trial examining the use of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area, a location for which the Solia S lead is not currently approved.